Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) not eligible for transplant.
Critère d'inclusion
- Relapsed Diffuse Large B-Cell Lymphoma,Refractory Diffuse large B-cell lymphoma